Format

Send to

Choose Destination
J Pediatr. 2006 Oct;149(4):572-5.

Adalimumab therapy for childhood uveitis.

Author information

1
Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.

Abstract

Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.

PMID:
17011337
DOI:
10.1016/j.jpeds.2006.04.058
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center